AstraZeneca HORIZON
A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children with Severe Uncontrolled Asthma (HORIZON)
- Sex: Any
- Age: Child (Birth - 17)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Lung, Asthma
Study Purpose
The purpose of this study is to learn more about a drug called tezepelumab (referred to as the “study drug”), when given to children aged 5 to less than 12 years old. The study will look at the effect the study drug has on your child’s asthma symptoms and will also determine how safe the study drug is when given to children. The study will also be used to better understand asthma and other associated health problems in children.
Who Can Participate
Age: 5-12 years old
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00002052
- StudyID: 2023-01218
- ClinicalTrials.gov: NCT06023589
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422